Related Experiment Video
Updated: Jan 8, 2026

07:45
Retroductal Nanoparticle Injection to the Murine Submandibular Gland
Published on: May 3, 2018
10.6K
Efficacy of Submucosal Polydeoxyribonucleotide Injection after Impacted Mandibular Third Molar Extraction: A
Hyun Joong Kim1, Seo Yeon Park1, Hyungjin Kwon1
1Department of Oral and Maxillofacial Surgery, Wonju Severance Christian Hospital, Yonsei University, Wonju, Korea.
Yonsei Medical Journal
|December 23, 2025
Summary
Polydeoxyribonucleotide (PDRN) injections effectively reduced pain and swelling after impacted mandibular third molar extraction. This treatment offers a promising option for managing post-extraction complications.
Area of Science:
- Oral and Maxillofacial Surgery
- Regenerative Medicine
Background:
- Impacted mandibular third molar (IMTM) extraction is a common surgical procedure.
- Postoperative complications such as pain and swelling can significantly impact patient recovery.
Purpose of the Study:
- To evaluate the efficacy of polydeoxyribonucleotide (PDRN) injections in mitigating postoperative complications following IMTM extraction.
- To assess the impact of PDRN on pain, swelling, periodontal pocket depth, and patient-reported outcomes.
Main Methods:
- A randomized, controlled clinical trial involving 30 patients undergoing bilateral IMTM extraction.
- PDRN was injected on one side (experimental), while normal saline was administered on the contralateral side (control).
- Outcomes measured included visual analog scale for pain, Laskin method for swelling, 3D volumetric analysis, periodontal probing depth, and patient-centered outcome questionnaires.
Main Results:
- Statistically significant reductions in postoperative pain and swelling were observed on the PDRN-treated side compared to the control side.
- PDRN demonstrated a positive effect in reducing patient discomfort and improving subjective perceptions of recovery.
Conclusions:
- PDRN injection appears to be a viable option for reducing postoperative pain and swelling after IMTM extraction.
- Further randomized controlled trials are warranted to confirm these findings and establish PDRN's clinical utility.

